Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2007

View Archived Issues

TMC-435350 safe in phase I trial in heathy volunteers

MQX-503 reduces the severity of Raynaud's phenomenon in clinical studies

Glycine, D-cycloserine ineffective in CONSIST schizophrenia trial

Efficacy similar with naproxcinod and naproxen in osteoarthritis patients

Niacin/laropiprant combined with simvastatin improves dyslipidemia

Risperidone beneficial in refractory major depressive disorder

Inhibitex obtains license for HCV polymerase inhibitors from U.K. and Belgian universities

Bone Medical initiates phase I/II clinical trial of oral CaPTHymone for osteoporosis

Cytos Biotechnology reports positive results from three phase IIa clinical trials of CYT004-MelQbG10

Novo Nordisk reports positive results from phase II study of liraglutide for obesity

Recent GSK patent discloses new antiinfective agents

New treatments for metabolic disorders reported in recent IRM and Schering patents

Recent patents describe novel agents for psychiatric disorders

Meyer obtains license from AnGes for NF-kappaB decoy for inflammatory disease

Merck & Co. suspends enrollment in clinical trials of kinase inhibitor MK-0457

EMEA recommends suspension of marketing authorization of medicines containing aprotinin

Cardiome initiates phase I study of GED-aPC

Avexa initiates two phase III clinical trials of apricitabine for drug-resistant HIV

Chinese Food and Drug Administration approves GNI's NDA for F-351

Arpida reports positive results from phase I trial of intravenous iclaprim

Hana initiates phase II clinical trial of Marqibo for metastatic malignant uveal melanoma

Medivir initiates TMC-435350-C201 phase IIa study of protease inhibitor TMC-435350

GlaxoSmithKline acquires Reliant Pharmaceuticals for USD 1.65 billion

Coley Pharmaceutical patents novel cytokine production promoters

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...